

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health ([NIH \(http://www.nih.gov\)](http://www.nih.gov))

Components of Participating Organizations

National Cancer Institute ([NCI \(http://www.nci.nih.gov/\)](http://www.nci.nih.gov/))

National Institute on Aging (NIA)

Funding Opportunity Title

The Role of Mobile Genetic Elements in Cancer (R01)

Activity Code

[R01 \(http://grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=r01&Search.x=0&Search.y=0&Search_Type=Activity\)](http://grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=r01&Search.x=0&Search.y=0&Search_Type=Activity) Research Project Grant

Announcement Type

New

Related Notices

None

Funding Opportunity Announcement (FOA) Number

PAR-16-227

Companion Funding Opportunity

[PAR-16-226 \(http://grants.nih.gov/grants/guide/pa-files/PAR-16-226.html\)](http://grants.nih.gov/grants/guide/pa-files/PAR-16-226.html), [R21 \(http://grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=r21&Search.x=0&Search.y=0&Search_Type=Activity\)](http://grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=r21&Search.x=0&Search.y=0&Search_Type=Activity)

Exploratory/Developmental Grant

Number of Applications

See [Section III. 3. Additional Information on Eligibility.](#)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.396, 93.866

Funding Opportunity Purpose

The overall goal of this funding opportunity announcement (FOA) is to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements, in cancer. For example, although long interspersed element-1 (LINE-1 or L1) retroelements are active in many cancers whether somatic L1 insertions lead to cancer cell heterogeneity and/or adaptive phenotypes that confer growth or survival advantages during cancer evolution or response to therapy is not clear. Similarly, how human endogenous viruses (HERVs) affect cancer processes is also not well understood. In an effort to address this knowledge gap, this FOA invites research applications that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their activity on tumor heterogeneity, cancer evolution, and response to therapy.

Key Dates

Posted Date

May 5, 2016

Open Date (Earliest Submission Date)

September 5, 2016

Letter of Intent Due Date(s)

Not Applicable

Application Due Date(s)

Standard dates apply, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

Standard dates apply by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Scientific Merit Review

Standard dates apply

Advisory Council Review

Standard dates apply

Earliest Start Date

Standard dates apply

Expiration Date

September 8, 2019

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the [SF424 \(R&R\) Application Guide \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=12000\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=12000), except where instructed to do otherwise (in this FOA or in a Notice from the [NIH Guide for Grants and Contracts \(http://grants.nih.gov/grants/guide/\)](http://grants.nih.gov/grants/guide/)). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in [Section IV](#). When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. **Applications that do not comply with these instructions may be delayed or not accepted for review.**

There are several options to submit your application to the agency through Grants.gov. You can use the ASSIST system to prepare, submit and track your application online. You can download an application package from Grants.gov, complete the forms offline, submit the completed forms to Grants.gov and track your application in eRA Commons. Or, you can use other institutional system-to-system solutions to prepare and submit your application to Grants.gov and track your application in eRA Commons. [Learn more \(http://grants.nih.gov/grants/ElectronicReceipt/preparing.htm#2\)](http://grants.nih.gov/grants/ElectronicReceipt/preparing.htm#2).

Apply Online Using ASSIST**Apply Using Downloadable Forms**

Problems accessing or using ASSIST should be directed to the [eRA Service Desk \(http://grants.nih.gov/grants/ElectronicReceipt/support.htm#desk\)](http://grants.nih.gov/grants/ElectronicReceipt/support.htm#desk).

Problems downloading forms should be directed to [Grants.gov Customer Support \(http://www.grants.gov/contactus/contactus.jsp\)](http://www.grants.gov/contactus/contactus.jsp).

Table of Contents

[Part 1. Overview Information](#)[Part 2. Full Text of the Announcement](#)

[Section I. Funding Opportunity Description](#)

[Section II. Award Information](#)

[Section III. Eligibility Information](#)

[Section IV. Application and Submission Information](#)

[Section V. Application Review Information](#)

[Section VI. Award Administration Information](#)

[Section VII. Agency Contacts](#)

[Section VIII. Other Information](#)

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Purpose

The overall goal of this concept is to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements, in cancer. For example, although L1 retroelements are active in many cancers whether somatic L1 insertions lead to cancer cell heterogeneity and/or adaptive phenotypes that confer growth or survival advantages during cancer evolution or response to therapy is not clear. Similarly, how human endogenous viruses (HERVs) affect cancer processes is also not well understood. In an effort to address this knowledge gap, this FOA invites research applications that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their activity on tumor heterogeneity, cancer evolution, and response to therapy.

This FOA is suitable for projects where proof-of-principle of the proposed technology or methodology has already been established and supportive preliminary data are available. This FOA runs in parallel with an FOA of identical scientific scope, [PA-16-226 \(http://grants.nih.gov/grants/guide/pa-files/PAR-16-226.html\)](http://grants.nih.gov/grants/guide/pa-files/PAR-16-226.html), which utilizes the Exploratory/Developmental Grant (R21) mechanism.

Background

The human genome and endogenous retroviruses: Roughly one-half of the human genome is comprised of repetitive sequences attributed to the evolutionary activities of mobile genetic elements including retrotransposons, DNA transposons, and endogenous retroviruses (ERVs). Retrotransposons and ERVs propagate via a copy-and-paste mechanism using an RNA intermediate while DNA transposons mobilize using a cut-and-paste mechanism. Although DNA transposons and human ERVs (HERVs) are not generally considered capable of mobilizing in the human genome, full-length long interspersed element-1 (LINE-1 or L1) retrotransposons have retained the ability to autonomously transpose – i.e., insert copies of themselves at new locations throughout the genome - and can also act in *trans* to mediate transposition of Alu short interspersed element (SINE) and host RNA sequences. While the majority of L1 elements in the human genome are no longer transposition competent, due to mutations and/or truncations, in any given individual, approximately 100 L1s have intact sequences, and a smaller subset (designated hot L1s), are capable of being transcribed and expressing the transposition machinery comprised of an ORF1 RNA binding protein and ORF2 endonuclease and reverse transcriptase.

L1 activity and retrotransposon-mediated insertions: L1 activity is normally suppressed in somatic cells by both transcriptional (heterochromatinization) and post-transcriptional (microRNA, and APOBEC) mechanisms, however, transient derepression of L1 loci and somatic retrotransposition has been observed in a number of developmental contexts that have been suggested to contribute to both normal development and disease. For

example, epigenetic reprogramming in oocyte development led to L1 activity and high levels of L1 insertions correlated with oocyte cell death. In neuronal progenitor cells, somatic L1 insertions have been reported to drive neural diversification and plasticity in the brain and L1 insertions have further been speculated to contribute to mental disorders. Lastly, derepression of L1 loci has been linked to excessive DNA damage associated with advanced age, suggesting a further connection between L1 activity and/or somatic insertions and age-associated disease pathogenesis. Thus, retrotransposon-mediated insertion in somatic tissues is emerging as a potentially important source of intra-individual genetic variation underlying normal developmental processes and disease pathogenesis.

Implications of L1 insertion events in cancer: Recent high-throughput analyses have revealed that somatic L1 insertions are also widespread in a number of human cancers. Computational approaches to map mobile genetic element insertions across a variety of tumor types have reported that L1 insertions occur at high frequency in epithelial cancers. However, even within a specific cancer type, the extent of L1 activity varied across patient samples suggesting that L1 mobilization is not necessarily a driver event. Further, somatic L1 insertions were enriched in regions of cancer-specific hypomethylation and often found embedded in non-coding regions of commonly mutated genes, including tumor suppressors, disrupting their expression. Further, emerging evidence suggests that specific L1 insertions are clonally selected during tumor evolution. Taken together, these findings strongly suggest that L1 expression or activity (and potentially other mobile genetic elements) can have a profound impact on tumor heterogeneity and adaptation during cancer progression.

HERV retroelements are remnants of exogenous retroviruses that have become fixed in the human genome but are no longer considered capable of mobilization due to extensive deletions and mutations. HERV transcripts and proteins have been observed in human cancers and HERV-K has been reported to form particles. Interestingly, HERV-encoded long non-coding RNAs have been speculated to rewire gene regulatory circuits in cancer cells. Despite these exciting observations, the role of HERVs in cancer etiology has yet to be fully understood.

Specific Research Objectives

Although it is clear that L1 retroelements are active in many cancers, whether somatic L1 insertions lead to cancer cell heterogeneity and/or adaptive phenotypes that confer growth or survival advantages during cancer evolution or response to therapy is not clear. In an effort to address this knowledge gap, this funding opportunity announcement invites research applications that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their mobilization on tumor heterogeneity, cancer evolution, and response to therapy.

Applicable research directions could include, but not be limited to, the following:

- Identify the networks that regulate retroelement expression/activity - including the role of host restriction factors and chimeric interactions between host and L1-encoded ORF proteins.
- Examine retroelement fitness and selection mechanisms in cancer cells that confer adaptive phenotypes.
- Determine the role of retroelement mobilization in sensitivity and resistance to cancer therapeutics.
- Establish the role of retroelement expression/activity in genomic instability and cancer initiation.
- Develop improved model systems (including cell culture systems and animal models) to uncover mechanistic principals of L1 expression and transposition in humans.
- Understand the genetic (and epigenetic) features that target somatic L1 insertions to sites in the genome.
- Evaluate the effect of non-nucleoside reverse transcriptase inhibitors (NRTIs) on L1 expression and transposition.
- Investigate the role of age-related activation of retroelements in cancer etiology.
- Assess how mobile genetic elements impact tumor-stroma interactions including interactions between

cancer cells and the immune system (or anti-tumor immune response).

- Develop improved technologies that reliably and comprehensively genotype L1 somatic insertions.
- Distinguish cancer-specific insertions from pre-existing background somatic transpositions, such as longitudinal studies or single cell analyses.
- Better understand Alu retrotransposition in cancer – which at present is very incomplete.
- Explore roles of DNA transposons or human endogenous retroviruses (HERVs) in cancer.

Enabling research efforts in this area are expected stimulate an improved understanding of mobile genetic elements in cancer progression.

See [Section VIII. Other Information](#) for award authorities and regulations.

Section II. Award Information

Funding Instrument

Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.

Application Types Allowed

New
Resubmission
Revision

The [OER Glossary \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11116\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11116) and the SF424 (R&R) Application Guide provide details on these application types.

Funds Available and Anticipated Number of Awards

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award Budget

Application budgets are not limited but need to reflect the actual needs of the proposed project. **Award Project Period**

The maximum project period is 5 years.

NIH grants policies as described in the [NIH Grants Policy Statement \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11120\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11120) will apply to the applications submitted and awards made in response to this FOA.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions

- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

- Small Businesses
- For-Profit Organizations (Other than Small Businesses)

Governments

- State Governments
- County Governments
- City or Township Governments
- Special District Governments
- Indian/Native American Tribal Governments (Federally Recognized)
- Indian/Native American Tribal Governments (Other than Federally Recognized)
- Eligible Agencies of the Federal Government
- U.S. Territory or Possession

Other

- Independent School Districts
- Public Housing Authorities/Indian Housing Authorities
- Native American Tribal Organizations (other than Federally recognized tribal governments)
- Faith-based or Community-based Organizations
- Regional Organizations
- Non-domestic (non-U.S.) Entities (Foreign Institutions)

Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) **are** eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations **are** eligible to apply.

Foreign components, as [defined in the NIH Grants Policy Statement \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11118\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11118), **are** allowed.

Required Registrations

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R)

Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The [NIH Policy on Late Submission of Grant Applications \(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-039.html\)](http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-039.html) states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

- [Dun and Bradstreet Universal Numbering System \(DUNS\) \(http://fedgov.dnb.com/webform\)](http://fedgov.dnb.com/webform) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
- [System for Award Management \(SAM\) \(https://www.sam.gov/portal/public/SAM/\)](https://www.sam.gov/portal/public/SAM/) (formerly CCR) – Applicants must complete and maintain an active registration, **which requires renewal at least annually**. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
 - [NATO Commercial and Government Entity \(NCAGE\) Code \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11176\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11176) – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
- [eRA Commons \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11123\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11123) - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
- [Grants.gov \(http://www.grants.gov/web/grants/applicants/organization-registration.html\)](http://www.grants.gov/web/grants/applicants/organization-registration.html) – Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

2. Cost Sharing

This FOA does not require cost sharing as defined in the [NIH Grants Policy Statement. \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11126\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11126)

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
- An application that has substantial overlap with another application pending appeal of initial peer review (see [NOT-OD-11-101 \(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-101.html\)](http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-101.html)).

Section IV. Application and Submission Information

1. Requesting an Application Package

Applicants must obtain the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at [Grants.gov \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11127\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11127).

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the [SF424 \(R&R\) Application Guide \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=12000\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=12000), including [Supplemental Grant Application Instructions \(https://grants.nih.gov/grants/guide/url_redirect.htm?id=82216\)](https://grants.nih.gov/grants/guide/url_redirect.htm?id=82216) except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit [Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=41137\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=41137).

Page Limitations

All page limitations described in the SF424 Application Guide and the [Table of Page Limits \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11133\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11133) must be followed.

Instructions for Application Submission

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed.

R&R or Modular Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

R&R Subaward Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Research Plan

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

PHS Inclusion Enrollment Report

When conducting clinical research, follow all instructions for completing PHS Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.

PHS Assignment Request Form

All instructions in the SF424 (R&R) Application Guide must be followed.

Foreign Institutions

Foreign (non-U.S.) institutions must follow policies described in the [NIH Grants Policy Statement](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11137) (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11137), and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

[Part I. Overview Information](#) contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or [Federal holiday](http://www.opm.gov/Operating_Status_Schedules/fedhol/2010.asp) (http://www.opm.gov/Operating_Status_Schedules/fedhol/2010.asp), the application deadline is automatically extended to the next business day.

Organizations must submit applications to [Grants.gov](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11128) (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11128) (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the [eRA Commons](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11123) (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11123), NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to [intergovernmental review](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11142). (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11142)

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the [NIH Grants Policy Statement](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11120) (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11120).

Pre-award costs are allowable only as described in the [NIH Grants Policy Statement](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11143) (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11143).

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. [Section III. Eligibility Information](#) contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit [Applying Electronically](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11144) (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11144). If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the [Guidelines for Applicants Experiencing System Issues](http://grants.nih.gov/grants/ElectronicReceipt/support.htm#guidelines) (<http://grants.nih.gov/grants/ElectronicReceipt/support.htm#guidelines>). For assistance with application submission, contact the Application Submission Contacts in [Section VII](#).

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See [Section III](#) of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See [more tips](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11146) (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11146) for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH. Applications that are incomplete or non-compliant will not be reviewed.

Requests of \$500,000 or more for direct costs in any year

Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a [Scientific/ Research Contact](#) at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request \$500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in [NOT-OD-13-030](http://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-030.html) (<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-030.html>).

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process. As part of the [NIH mission \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11149\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11149), all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Investigator(s)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Approach

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?

Environment

Will the scientific environment in which the work will be done contribute to the probability of success? Are the

institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

Protections for Human Subjects

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the [Guidelines for the Review of Human Subjects \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11175\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11175).

Inclusion of Women, Minorities, and Children

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the [Guidelines for the Review of Inclusion in Clinical Research \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11174\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11174).

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the [Worksheet for Review of the Vertebrate Animal Section \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11150\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11150).

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.

Renewals

Not Applicable

Revisions

For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.

Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Applications from Foreign Organizations

Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) [Data Sharing Plan \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11151\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11151); (2) [Sharing Model Organisms \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11152\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11152); and (3) [Genomic Data Sharing Plan \(GDS\) \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11153\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11153).

Authentication of Key Biological and/or Chemical Resources:

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review, in accordance with [NIH peer review policy and procedures \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11154\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11154), using the stated [review criteria](#). Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

- May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
- Will receive a written critique.

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or

Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:

- Scientific and technical merit of the proposed project as determined by scientific peer review.
- Availability of funds.
- Relevance of the proposed project to program priorities.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the [eRA Commons \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11123\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11123). Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the [NIH Grants Policy Statement \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11156\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11156).

Section VI. Award Administration Information

1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the [NIH Grants Policy Statement \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11157\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11157).

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee's business official.

Awardees must comply with any funding restrictions described in [Section IV.5. Funding Restrictions](#). Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the [Award Conditions and Information for NIH Grants \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11158\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11158) website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the [NIH Grants Policy Statement \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11120\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11120) as part of the NoA. For these terms of award, see the [NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11157\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11157) and [Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11159\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11159). More information is provided at [Award Conditions and Information for NIH Grants \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11158\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11158).

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person's race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator's scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see <http://www.hhs.gov/ocr/civilrights/resources/laws/revisedlep.html>. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see <http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html> (<http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html>); and <http://www.hhs.gov/ocr/civilrights/understanding/index.html> (<http://www.hhs.gov/ocr/civilrights/understanding/index.html>). Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html> (<http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>). Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at <http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html> (<http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html>) or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at <http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53> (<http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53>).

Cooperative Agreement Terms and Conditions of Award

Not Applicable

3. Reporting

When multiple years are involved, awardees will be required to submit the [Research Performance Progress Report \(RPPR\)](http://grants.nih.gov/grants/rppr/index.htm) (<http://grants.nih.gov/grants/rppr/index.htm>) annually and financial statements as required in the [NIH Grants Policy Statement](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11161). (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11161)

A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the [NIH Grants Policy Statement](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11161) (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11161).

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at [www.fsrs.gov](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11170) (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11170) on all subawards over \$25,000. See the [NIH Grants Policy Statement](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11171) (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11171) for additional information on this reporting requirement.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Service Desk (Questions regarding ASSIST, eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post submission issues)

Finding Help Online: <http://grants.nih.gov/support/> (<http://grants.nih.gov/support/>) (preferred method of contact)

Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

[Grants.gov Customer Support \(http://www.grants.gov/web/grants/support.html\)](http://www.grants.gov/web/grants/support.html) (Questions regarding Grants.gov registration and submission, downloading forms and application packages)

Contact Center Telephone: 800-518-4726

Email: [support@grants.gov \(mailto:support@grants.gov\)](mailto:support@grants.gov)

GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)

Email: [GrantsInfo@nih.gov \(mailto:GrantsInfo@nih.gov\)](mailto:GrantsInfo@nih.gov) (preferred method of contact)

Telephone: 301-710-0267

Scientific/Research Contact(s)

T. Kevin Howcroft, Ph.D.

National Cancer Institute (NCI)

Telephone: 240-276-6200

Email: [Howcrofk@mail.nih.gov \(mailto:Howcrofk@mail.nih.gov\)](mailto:Howcrofk@mail.nih.gov)

(For general questions or those focused on cancer etiology or immunology)

Michael Graham Espey, Ph.D.

National Cancer Institute (NCI)

Telephone: 240-276-7619

Email: [espeym@mail.nih.gov \(mailto:espeym@mail.nih.gov\)](mailto:espeym@mail.nih.gov)

(For questions on cancer cell biology)

Elisa Woodhouse, Ph.D.

National Cancer Institute (NCI)

Telephone: 240-276-6220

Email: [woodhousee@mail.nih.gov \(mailto:woodhousee@mail.nih.gov\)](mailto:woodhousee@mail.nih.gov)

(For questions on the tumor microenvironment or metastasis)

Max Guo, Ph.D.

National Institute on Aging (NIA)

Telephone: 301-402-7747

Email: [max.guo@nih.gov \(mailto:max.guo@nih.gov\)](mailto:max.guo@nih.gov)

Peer Review Contact(s)

Michael Bloom, Ph.D.

Center for Scientific Review (CSR)

Telephone: 301-451-0132

Email: [bloomm2@mail.nih.gov \(mailto:bloomm2@mail.nih.gov\)](mailto:bloomm2@mail.nih.gov)

Financial/Grants Management Contact(s)

Long Nguyen

National Cancer Institute (NCI)

Telephone: 240-276-5807

Email: [Long.Nguyen@nih.gov \(mailto:Long.Nguyen@nih.gov\)](mailto:Long.Nguyen@nih.gov)

Linda Christine Whipp

National Institute on Aging (NIA)

Telephone: 301-402-7731

Email: whipl@nia.nih.gov (<mailto:whipl@nia.nih.gov>)

Section VIII. Other Information

Recently issued trans-NIH [policy notices \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11163\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11163) may affect your application submission. A full list of policy notices published by NIH is provided in the [NIH Guide for Grants and Contracts \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11164\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11164). All awards are subject to the terms and conditions, cost principles, and other considerations described in the [NIH Grants Policy Statement \(http://grants.nih.gov/grants/guide/url_redirect.htm?id=11120\)](http://grants.nih.gov/grants/guide/url_redirect.htm?id=11120).

Authority and Regulations


Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.

[Weekly TOC for this Announcement \(/grants/guide/WeeklyIndex.cfm?05-06-16\)](/grants/guide/WeeklyIndex.cfm?05-06-16)

[NIH Funding Opportunities and Notices \(/grants/guide/index.html\)](/grants/guide/index.html)

1





NIH... Turning Discovery Into Health®

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see [Help Downloading Files \(/grants/edocs.htm\)](/grants/edocs.htm).